FT : The electric car’s unstoppable drive

The electric car’s unstoppable drive
The revolution is coming. Better be prepared

Hardly a day passes without adding to the exciting prospects for electric vehicles. In recent weeks, both France and the UK have committed to phasing out petrol cars fully for new car purchases by 2040; Tesla has started selling its “mass market” model to intense interest; there is now even electric car racing under the brand of (what else) Formula E.

In the little time left before the future arrives, it is wise to contemplate the possible downsides. Reservations about electric vehicles come in two versions. One casts doubt on whether the heralded electric vehicle revolution will in fact overthrow the internal combustion engine as it promises to do. The second accepts that it will, but points out the negative consequences of the shift to electrically powered transport.

BP issued estimates in January this year that were distinctly cool on the electric revolution as it applies to transport energy. Its analysts foresaw electric cars to number 100m globally by 2040 — a huge leap from now but still only about 5 per cent of a projected total global fleet of 1.8bn cars. That total is about 50 per cent higher than today’s, with almost all the net growth accounted for by emerging economies. On this estimate, electric cars would make a negligible contribution to the control of carbon emissions.

As with most things renewable, events are making that forecast more pessimistic by the day. (BP itself acknowledges the deep uncertainty, pointing out that an extra 100m electric vehicles would reduce oil demand by 1.4m barrels a day.) On the technology side, even if electric vehicles cost more to purchase than conventional ones, the all-in usage cost now seems to be on a par. It surely will not take long for financing schemes to develop that will allow consumers to shift lifetime savings on electric car ownership into the present so that sticker prices also look the same. And there is no reason to think the progress in electrically powered transportation technology is about to slow down.


Policy, too, is smiling at electric vehicle adoption. Other analysts are much more bullish than BP, with, for example, Opec expecting 266m electric cars on the road and Bloomberg New Energy Finance projecting that electric vehicles will constitute 54 per cent of new global sales by 2040. If the French and British commitments stick, that number will be 100 per cent for those countries and any other that pursues the same policy. That’s shares of sales rather than the stock of existing cars — but unless electric vehicles disappoint massively, the stock will adjust to a steady state at those rates reasonably fast. (The average age of the car fleet is about 10-12 years in the EU and the US.) If so, we will be counting electric cars in the billions, not the tens of millions.

Turn to the other type of scepticism: reasons why a high rate of electric car take-up may not be something to cheer. My colleague Pilita Clark writes about a challenge that does not receive anywhere near enough attention. Because the electric motors are mechanically simpler and require less maintenance than combustion engines, electric vehicles require much less labour in their manufacturing and throughout their life cycle.

But this is always the flip side of greater labour productivity: technology allowing manufacturers to produce a larger number of products with fewer hands. A productivity boost from a shift to electric is not, in its effects, all that different from productivity advances in conventional car manufacturing. The US, for example, produces more cars and parts today than at the employment peak in 2000, with only two-thirds as many workers. One consequence of higher productivity is a better, cleaner and more efficient car for a given amount spent.

The FT’s Africa editor David Pilling draws attention to another dark side of electric vehicle manufacturing. The batteries they use rely on cobalt, which is overwhelmingly found in the Democratic Republic of Congo. In ill-governed environments such as Congo’s, mining tends to despoil the environment, fuel corruption and finance conflict. As demand for cobalt grows, this is likely to get worse.

The answer, at a minimum, must be efforts in the main markets for electric cars to set up transparency and regulations to force accountability throughout the supply chain. A possible model is conflict diamonds, and “publish-what-you-pay” rules for oil and mining, although even the former are not perfect and the latter are being rolled back in the US. Notwithstanding this, Pilling is right that a decent policy to minimise harm “should not be beyond the wit of the same clever people who invented the electric car”.

To the best of our knowledge, then, there is a distinct possibility that a massive electric car revolution is indeed under way, with side effects that must be seen in order to be managed. Better be prepared.

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
:
  • NXTD +16.4%, AHGP +14.1%, SSW +9.1%, SOHU +8.7%, DO +7.5%, PDS+5%, NRZ +5%, ANFI +4.1%, DAN +3.3%, OIS +2.1%, HSBC +1.8%, SF+1.3%, SNY +1.3%, BTG +1.1%, DISCA +1.1%, ARLP +1%
M&A news:
  • CHTR +6.7% (spokesperson says company is not interested in Sprint (S), but Softbank (SFTBY) might still be interested in CHTR acquisition, according to Reuters)
Other news:
  • ETRM +4.3% (received approval from the Ministry of Health, Social Services, and Equality to initiate a clinical trial for the Gastric Vest System in Spain; Enrollment is expected to begin by early 2018)
  • CLF +3.5% (commences $575 mln tack-on offering of its 5.75 percent senior guaranteed notes due 2025)
  • NADL +2.4% (amends the revolving credit facility provided by Seadrill (SDRL))
  • AMD +1.4% (unveiled new professional graphics cards)
  • RIO +1.4% (Rio Tinto and Unifor union agree to 4 year agreement with 3% wage increase this year)
  • JD +1.3% (in sympathy with BIDU upgrade)
  • TMUS +1.2% (trading higher with CHTR and S)
  • TSLA +1.1% (CEO Elon Musk confirms first Model 3 deliveries with 500K reservations in advance)
  • WDC +0.9% (issues statement regarding the order of the Superior Court of California for the County of San Francisco)
  • AZN +0.9% (receives Breakthrough Therapy Designation from FDA for Imfinzi)
Analyst comments:
  • GPRO +3.1% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
  • AXGN +2.6% (initiated with a Outperform at Leerink Partners)
  • BIDU +1.5% (upgraded to Buy from Neutral at Nomura)
  • CRTO +1.4% (initiated with a Overweight at KeyBanc Capital Mkts)
  • ICLR +1.3% (upgraded to Buy from Hold at SunTrust)
  • CELG +0.7% (upgraded to Buy from Hold at Argus)

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
:
  • ICPT -4.1%, CYOU -1.6%, VDTH -1.4%
Other news:
  • TENX -36.2% (provides regulatory update following discussions regarding path forward for levosimendan; is continuing its review of strategic alternatives)
  • DRYS -6.7% (provides another Kalani Investments update)
  • CLVS -5.4% ( to collaborate with Bristol-Myers (BMY) to evaluate the combination of Opdivo and Rubraca in pivotal phase 3 clinical trials in Advanced ovarian cancer and Advanced triple-negative breast cancers)
  • REGN -3.1% (maybe be related to item in SNY earnings which reported partnered drug dupixent revs of ~$30 mln)
  • SNAP -2.8% (lockup expiration, accd to CNBC)
  • FEYE -2.5% (report of a possible data breach)
  • IBKR -1.7% (files for Class A Common Stock common stock shelf offering)
  • RYAAY -1.5% (Barron's profiles cautious view on Ryanair)
Analyst comments:
  • HTZ -5.4% (downgraded to Underweight from Equal Weight at Barclays)
  • EGO -3.5% (downgraded to Underperform from Neutral at Credit Suisse)
  • CFR -1.5% (downgraded to Underweight from Neutral at JP Morgan)
  • ULTA -0.7% (downgraded to Perform from Outperform at Oppenheimer)

(GS) Tesla Thoughts post Model 3 launch into 2Q17 earnings (expect miss)

* What's changed
We attended Tesla’s Model 3 delivery launch event on July 28, taking rides
in both the Model 3 and Model S products. In our view, the event was a bit
anticlimactic, with no noticeable incremental features moving from the
Model 3 unveil to production model. That said, Tesla does now have a
lower-priced vehicle in production and 500k orders. However, CEO
commentary was slightly cautious on the upcoming prospects of hitting its
communicated launch curve – a key tenet of our Sell call. Lastly, we tweak
our 2Q17 estimates slightly for a lower gross margin given mix issues; we
continue to expect a miss and downward estimate revision for 2H17E.

* Implications
To the positive: Production Model 3 unveiled, with Tesla releasing two
variants: the Standard ($35k base / 220 mile range), and the Long Range
($44k base / 310 mile range). Model 3 reservations now over 500k, up
from 373k in May 2016 – indicating continuing follow-through demand. To
the negative: We expect Auto gross margins to disappoint as 2Q17
(GSe 24.3% vs. guide of approx. 25.3%) likely impacted by production mix
issues with the 100 kWh battery-size vehicles in the quarter. Further, we
maintain that 2H17 margins will be diluted due to Model 3 (GSe 16% vs.
Street 24%). No incremental features: Model 3 remains a de-contented,
smaller version of the Model S; and the production vehicle showed no
incremental HMI features from the vehicle unveiled last year. Our top
questions for earnings: Pace of demand for the Model S, 2H17 gross
margin guidance, and expected timing for next capital raise.

* Valuation
Our 6-month, $180 price target is derived from our probability weighted
Automotive ($138), Tesla Energy ($35), and SolarCity ($7) valuations.

* Key risks
Model 3 production cadence, stronger Model S/Model X demand, positive
free cash flow generation, and incremental new product announcements

(DBK) Carrefour – cut to SELL: expensive after price/promo investment. Tgt cut 2

1/ We cut our rating to Sell, our EPS estimates by 14% and TP to E18

2/ We think Carrefour, with a new CEO, will need material price + promo repositioning to fix its French hypers

3/ In 2012 the price cap to main competitor Leclerc was just 0.6%, it is now 6%
# resetting that price gap would eliminate all the French EBIT (costs cannot offset it). Carrefour can’t be that aggressive

4/ Further, Carrefour is badly behind in online, with a just an 8% market share vs 48% for Leclerc

5/ The recent Brazil IPO, pricing at the bottom of the range (just 8x EV/EBITDA) has not provided material value creation

6/ Carrefour is expensive on FCF yld: 2.6% in 2017. Its capex is not going to fall far enough to change that lack of cash generation

>>> ICPT - CONTROL Trial shows Statin Therapy Reversed LDL increases to below ba

Potential read across for Genfit

CONTROL Trial shows Statin Therapy Reversed LDL increases to below baseline levels in NASH patients treated with OCA 
Announced results from CONTROL, a placebo-controlled trial to prospectively characterize the lipid metabolic effects of obeticholic acid (OCA) and concomitant statin administration in patients with nonalcoholic steatohepatitis (NASH) with fibrosis or cirrhosis. The CONTROL trial met its primary objective by showing that newly initiated treatment with atorvastatin rapidly reversed OCA-associated increases in LDL to below baseline levels. Most of the effect was observed four weeks after initiation of the lowest available dose of atorvastatin and was sustained throughout the study period. 

CONTROL is a 16-week double-blind, placebo-controlled, dose-ranging study of 84 NASH patients with fibrosis and compensated cirrhosis, followed by a two-year long term safety extension (LTSE) open label phase which is currently ongoing. Lipid changes were assessed every four weeks over the course of the double-blind phase. Details of the study design are as follows:
* Statin-naïve or washout patients were randomized to receive one of three doses of OCA (5 mg, 10 mg or 25 mg) or placebo.
* At week four, the lowest approved dose of atorvastatin (10 mg) was added in all patients.
* At week eight, patients were titrated to the next highest prescribed dose of atorvastatin (20 mg).
* At week 12, further titration of atorvastatin (up to 40 mg) was permitted at investigators’ discretion.

The study was designed to measure treatment differences within each group relative to baseline. The intent-to-treat (ITT) analysis is shown below and includes all patients who received at least one dose of study medication.
At week four, mean LDL levels increased in each of the OCA treatment groups, while remaining relatively unchanged in the placebo group. The addition of 10 mg of atorvastatin rapidly reversed mean LDL to below baseline levels in all OCA treatment groups at the first assessed time point (week eight), and this effect was sustained through week 16. The observed mean LDL reductions in the OCA groups were approximately 40 – 45 mg/dL while placebo was 48 mg/dL.

FT Lex : Tobacco: smoke signals

Tobacco: smoke signals
Nicotine regulation may never happen, while ecigarette news is positive

The Trump administration is making little legislative headway. But it can at least slash regulations with gusto. Surprising, then, that a government that has rolled back rules on power plant emissions should propose new ones on personal lung pollution.

Shares in Altria have fallen 9 per cent and British American Tobacco by 7 per cent since the Food and Drug Administration said it aimed to reduce nicotine in cigarettes to lessen their addictive properties, while supporting new safer alternatives.

The sell-off was not universal, however. Philip Morris International shares, after a brief dip in sympathy with the sector, ended up in positive territory on Friday. PMI, which sells Marlboro internationally after its spin-off from Altria in 2008, has an advantage; the Switzerland-based company can dodge the rules thanks to its focus outside the US. BAT, however, paid $49bn in January for the remaining stake in Reynolds American, maker of Newports and Camel.

Yet the US is not such a hostile place for Big Tobacco. Altria’s sell-off, which went as far as 19 per cent at one stage on Friday, looks exaggerated. Even as the number of smokers in the US has continued to fall, industry revenues have risen thanks to higher prices. Last year volume sales fell 2 per cent to 263.4bn cigarettes, while the value rose 1 per cent to $94.4bn, according to Euromonitor International. BAT’s bet is still good. 

Of course the industry remains vulnerable to government intervention. But there is a long way to go before any new restrictions are implemented. The permissive attitude to ecigarettes, the other side of the proposal, is more likely to stick. All should benefit — but none more so than PMI, which possesses one of the most promising ecigarettes. Even before Friday, Wells Fargo estimated it would be enough to reverse declining revenues and more than double earnings growth. Rather than bask in its remoteness from the US, it can seize the moment.

>>> EU Commission said to consider measures considering measures which would all

EU Commission said to consider measures considering measures which would allow them to temporarily stop people withdrawing money from their accounts to prevent bank runs - financial press 
- Move is aimed at helping rescue lenders that are deemed failing or likely to fail 
- Proposal comes less than two months after a run on deposits at Banco Popular contributed to the collapse of the Spanish lender

FT : JPMorgan develops robot to execute high-speed trades

JPMorgan develops robot to execute high-speed trades
Trial shows AI is more efficient than traditional methods of buying and selling

JPMorgan will soon be using a first-of-its-kind robot to execute trades across its global equities algorithms business, after a European trial of the bank’s new artificial intelligence (AI) programme showed it was much more efficient than traditional methods of buying and selling.

The AI — known internally as LOXM — has been used in the bank’s European equities algorithms business since the first quarter and will be launched across Asia and the US in the fourth quarter, Daniel Ciment, JPMorgan’s head of global equities electronic trading, told the Financial Times. 

LOXM’s job is to execute client orders with maximum speed at the best price, by using lessons it has learnt from billions of past trades — both real and simulated — to tackle problems such as how best to offload big equity stakes without moving market prices.

“Such customisation was previously implemented by humans, but now the AI machine is able to do it on a much larger and more efficient scale,” said David Fellah, of JPMorgan’s European Equity Quant Research team. Mr Ciment said that, so far, the European trials showed that the pricing achieved by LOXM was “significantly better” than its benchmark.

Investment banks have been trying to use AI, automation and robotics to help cut costs and eliminate time-consuming routine work. For example, UBS’s recent deployment of AI to deal with client post-trade allocation requests, which saves as much as 45 minutes of human labour per task. UBS has also brought in AI to help clients trade volatility.

JPMorgan, which is the world’s biggest investment bank by revenue, believes it is the first on Wall Street to use AI with trade execution and said it would take rivals 18 to 24 months and an investment of “multiple millions” to come up with similar technology. 

“Best execution is becoming more and more important to clients,” said Mr Ciment of JPMorgan’s decision to invest in the pioneering technology, adding that it could become part of the marketing pitch the bank makes to clients. 

The AI was developed using “Deep Reinforcement Learning” methods, which are able to learn from millions of historic scenarios. Mr Fellah said DRL has “many other potential uses in banking, such as in automatic hedging and market making”. 

One possible evolution of LOXM is teaching the machine how to get to know individual clients, so that it could consider the client’s behaviour and reaction as it decides how to trade. “Any customisation would only be if the client agrees to that,” Mr Ciment added.

Unlike the robo advisers offered by some private banks, JPMorgan’s AI has no decision-making capabilities around what is bought and sold, its role is solely to decide how things are bought and sold. 

The bank has had no risk management issues with the technology. “The machine is restricted in its trading behaviour, as it learns under, and operates within, our general electronic trading risk framework, which is overseen by internal control groups and validated by regulators,” Mr Fellah said.